Can You Repeat That? Exploring the Definition of a Successful Model Replication in Health Economics

Emma McManus (), David Turner and Tracey Sach
Additional contact information
Emma McManus: University of East Anglia
David Turner: University of East Anglia
Tracey Sach: University of East Anglia

PharmacoEconomics, 2019, vol. 37, issue 11, No 9, 1381 pages

Abstract: Abstract The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) modelling taskforce suggests decision models should be thoroughly reported and transparent. However, the level of transparency and indeed how transparency should be assessed are yet to be defined. One way may be to attempt to replicate the model and its outputs. The ability to replicate a decision model could demonstrate adequate reporting transparency. This review aims to explore published definitions of replication success across all scientific disciplines and to consider how such a definition should be tailored for use in health economic models. A literature review was conducted to identify published definitions of a ‘successful replication’. Using these as a foundation, several definitions of replication success were constructed, to be applicable to replications of economic decision models, with the associated strengths and weaknesses of such definitions discussed. A substantial body of literature discussing replicability was found; however, relatively few studies, ten, explicitly defined a successful replication. These definitions varied from subjective assessments to expecting exactly the same results to be reproduced. Whilst the definitions that have been found may help to construct a definition specific to health economics, no definition was found that completely encompassed the unique requirements for decision models. Replication is widely discussed in other scientific disciplines; however, as of yet, there is no consensus on how replicable models should be within health economics or what constitutes a successful replication. Replication studies can demonstrate how transparently a model is reported, identify potential calculation errors and inform future reporting practices. It may therefore be a useful adjunct to other transparency or quality measures.

Date: 2019
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-019-00836-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:37:y:2019:i:11:d:10.1007_s40273-019-00836-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-019-00836-y

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().